OBERADILOL

Details

Stereochemistry	MIXED
Molecular Formula	C25H30ClN5O3
Molecular Weight	483.99
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1CC(=O)NN=C1C2=CC=C(NCC(C)(C)NCC(O)COC3=CC(Cl)=CC=C3C#N)C=C2

InChI

InChIKey=SHAJOALCPZUGLR-UHFFFAOYSA-N

InChI=1S/C25H30ClN5O3/c1-16-10-23(33)30-31-24(16)17-5-8-20(9-6-17)28-15-25(2,3)29-13-21(32)14-34-22-11-19(26)7-4-18(22)12-27/h4-9,11,16,21,28-29,32H,10,13-15H2,1-3H3,(H,30,33)

HIDE SMILES / InChI

Molecular Formula	C25H30ClN5O3
Molecular Weight	483.99
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://adisinsight.springer.com/drugs/800002312
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/9147023,9468640,7912931

TZC-5665 (Oberadilol) is a pyridazinone derivative with vasodilatory and beta-adrenergic blocking activities and type III phosphodiesterase inhibitory action

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9147023 \| http://www.ncbi.nlm.nih.gov/pubmed/7912931	Antagonist 2849
cyclic-nucleotide phosphodiesterase activity 3 Target ID: GO:0004112 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9147023 \| http://www.ncbi.nlm.nih.gov/pubmed/7912931	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heart failure 106 Sources: http://adisinsight.springer.com/drugs/800002312	Primary		Phase II 1147	Unknown Approved Use Unknown
Hypertension 575 Sources: http://adisinsight.springer.com/drugs/800002312	Primary		Preclinical	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
6 mg single, oral Highest studied dose Dose: 6 mg Route: oral Route: single Dose: 6 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9147023/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/9147023/	Sources: https://pubmed.ncbi.nlm.nih.gov/9147023/

PubMed

Title	Date	PubMed
Studies on agents with vasodilator and beta-blocking activities. V. Synthesis and pharmacological activity of the optical isomers of TZC-5665.	1998-01	9468640
Cardiac and hemodynamic effects of TZC-5665, a novel pyridazinone derivative, and its metabolite in humans and dogs.	1997-04	9147023
Cardiac effects of the novel pyridazinone derivative 6-[4-[2-[3-(5-chloro-2-cyanophenoxy)-2-hydroxypropylamino]- 2- methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H) pyridazinone monoethyl maleate and its metabolite in isolated heart preparations of guinea pigs and dogs.	1994-05	7912931

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:11:23 GMT 2025` Edited by `admin` on `Mon Mar 31 18:11:23 GMT 2025`
Record UNII	7ZNX9ET039
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(±)-4-CHLORO-2-(3-((1,1-DIMETHYL-2-(P-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)ANILINO)ETHYL)AMINO)-2-HYDROXYPROPOXY)BENZONITRILE

Preferred Name

English

OBERADILOL

Official Name

English

Oberadilol [WHO-DD]

Common Name

English

oberadilol [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29707